Industry Spotlight: NeuroNOS

About NeuroNOS

NeuroNOS is a pioneering biopharmaceutical company dedicated to developing transformative treatments for Autism Spectrum Disorder and other complex neurological conditions. The company, a subsidiary of Beyond Air®, is focused on preclinical development of NeuroNOS’s small-molecule drug, designed as an injectable or oral treatment for children with autism. The drug leverages the regulation of nitric oxide (NO) levels in the brain to positively impact neurological function.

Research background

NO is a neurotransmitter and a signaling molecule in the brain, where it plays a central role in modulating neuronal functions. High levels of NO can result in nitrosative stress, which leads to toxicity and disrupts the normal functioning of the brain cells. Emerging evidence points to abnormal NO signaling, and the subsequent cellular stress, being implicated in autism.

The NeuroNOS drug under development stems from the innovative discoveries of Prof. Amal during his research at the School of Pharmacy at the Hebrew University of Jerusalem (HUJI) and currently a visiting professor at Harvard University. This research, published in the prestigious journal Advanced Science, showed that children with autism exhibit elevated NO levels.

The promising preclinical data from the research completed to date have demonstrated that by addressing NO imbalances in the brain, both underlying brain function and surface symptoms can be improved – inhibiting the production of NO production in the brain reversed autism-like symptoms in autism mice models and corrected pathological pathways in stem cell-derived neurons from children with autism.

Visit NeuroNOS website to learn more